Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?

AIDS

Volumn 21, Issue 5, 2007, Pages 599-606

  Cicconi, Paola ^a   Cozzi Lepri, Alessandro ^b   Phillips, Andrew ^b   Puoti, Massimo ^c   Antonucci, Giorgio ^d   Manconi, Paolo E ^e   Tositti, Giulia ^f   Colangeli, Vincenzo ^g   Lichtner, Miriam ^h   Monforte, Antonella D'Arminio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF BRESCIA   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF CAGLIARI   (Italy)

^f Vicenza Hospital   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

HAART; HIV HCV HBV co infection; Liver toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; INDINAVIR; LAMIVUDINE; LIVER ENZYME; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; POISSON DISTRIBUTION; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER; MALE; RISK ASSESSMENT;

EID: 33847224106     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328013db9c     Document Type: Article

References (25)

1. Wit FW, Waverling GJ, Weel J, Jurriaans S, Longe J. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral therapy. J Infect Dis 2002; 186 July.
2. Nunez M, Lana R, Mendoza JL, Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:426-431.
3. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Safety 2005; 28:53-66.
4. Puoti M, Torti C, Ripamonti D, Castelli S, Zaltron S, Zanini B, et al., for the HIV-HCV Co-Infection Study Group. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J AIDS 2003; 32:259-326.
5. Saves M, Vandentorren S, Daucourt V, Marimoutou C, Dupon M, Couzigou P, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999; 13:F115-F121.
6. Saves M, Vandentorren S, Daucourt V, Marimoutou C, Dupon M, Couzigou P, et al., for the NN Study Team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
7. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543-549.
8. Sulkowski M. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38:S90-S97.
9. Meraviglia P, Schiavini M, Castagna A, Vigano P, Bini T, Landonio S, et al. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Med 2004; 5:334-343.
10. Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine- and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS 2003; 14:776-781.
11. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268.
12. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleosid reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38 (Suppl 2):S80-S89.
13. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-2902.
14. Sulkowski M, Thomas D, Chasson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
15. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-189.
16. Servin-Abad L, Molina E, Baracco G, Arosemena L, Regev A, Jeffers L, et al. Liver enzymes elevation after HAART in HIV-HCV co-infection. J Viral Hepat 2005; 12:429-434.
17. Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40:588-593.
18. Nunez M, Rios P, Carbonero L, Perez-Olmeda M, Gonzalez-Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30:65-68.
19. Mehta SH, Netski D, Sulkowski MS, Strathdee SA, Vlahov D, Thomas DL. Liver enzyme values in injection drug users with chronic hepatitis C. Dig Liver Dis 2005; 37:674-680.
20. d'Arminio Monforte A, Pezzotti P, Arici C, Ippolito G, Rezza G, Angarano G, et al. Determinants of initiation of antiretroviral therapy (HAART) in an italian cohort of HIV-positive patients naive from antiretrovirals (ICoNA Study). AIDS 1998; 12:99. Database can be found at http://www.icona.org.
21. AIDS Clinical Trials Group. Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: National Institutes of Allergy and Infectious Diseases, Division of AIDS; 1992.
22. Macroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, et al., for the Eurosida Study Group. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21:527-536.
23. Kelleher T, Mehta S, Bhaskar R, Sulkowski M, Astemborski J, Thomas D, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. J Hepatol 2005; 43:78-84.
24. Aceti A, Pasquazzi C, Zechini B, De Bac C, for the LIVERHAHAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29:41-48.
25. Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, et al., for the HepaICoNA Study Group and the Italian Cohort of Naive for Antiretrovirals Study Group. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral naive HIV infected individuals. Clin Infect Dis 2005; 40:101-109.